Slingshot members are tracking this event:

Regeneron Pharmaceuticals (REGN) trial on DUPIXENT (dupilumab) in food allergy set to begin in second half of 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
REGN Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Dupixent, Dupilumab, Food Allergy